Thalassaemia gene therapy - Crucell

Drug Profile

Thalassaemia gene therapy - Crucell

Latest Information Update: 24 Jun 1998

Price : $50

At a glance

  • Originator Crucell
  • Class
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Thalassaemia

Most Recent Events

  • 24 Jun 1998 Discontinued-Preclinical for Thalassaemia in Netherlands (Injection)
  • 17 Nov 1997 New profile
  • 17 Nov 1997 Preclinical development for Thalassaemia in Netherlands (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top